The FDA paused a controversial practice of publicly releasing complete response letters (CRLs), citing litigation risk as it works toward a formal policy for future disclosures. The change follows legal pressure from an unnamed firm that challenged how CRLs are handled. In parallel, reporting indicates HHS is moving forward on additional rulemaking that would clarify the framework for CRL releases. That could affect how quickly companies get full agency reasoning in cases of drug application setbacks. For biotech developers, the procedural shift matters operationally: it can delay competitive intelligence, complicate investor messaging, and impact how teams respond to regulatory deficiencies across development timelines. The FDA’s stance also signals that transparency policies in drug review processes remain in flux, with the agency seeking a defensible legal basis before resuming broader disclosure.